Title(s):
RTOG 0614. A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0627. A Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0825. Phase III Double Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP B-39. A Phase III Randomized Study of Adjuvant Whole Breast Versus Partial Breast Irradiation in Women with Ductal Carcinoma in Situ or Stage I or II Breast Cancer.

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673).

Go to top

Title(s):
SWOG 0307. A Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU PACCT-1. CTSU Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP B-42. Registration Program to Provide Up to Three Years of Letrozole to Postmenopausal Women with Hormone Receptor Positive Breast Cancer Who have Received at Least Two Years of Initial Adjuvant Hormonal Therapy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP B-40. A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cnacer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood from pCR with each of the Regimens

Investigator(s):
Principal Investigator: Andrew Fenton, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0517. Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer

Investigator(s):
Principal Investigator: Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
ACOSOG Z1031. A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Investigator(s):
Principal Investigator: Daniel Guyton, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
NSAPB B-41. A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2 Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0622. A Phase II Study of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP FB-5. A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU E5103. A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU CALGB 40302. Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP B-44-1. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center, 330-344-HOPE (4673)

Go to top

Title(s):
NSABP B-43. A Phase II Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lympectomy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Center Research 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0715. Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy, Phase III

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 0219. A Phase III Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 0240. A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel with and without NCI Supplied Bevacizumab, in Stage IVb, Recurrent or Persistent Carcinoma of the Cervix

Investigator(s):
Principal Investigator, Eric Jenison, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU CALGB 80405. A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU N0147. A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5FU/Leucovorin (CF) after Curative Resection for Patients with Stage III Colon Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU E5202. A Randomizaed Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 0249. A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer

Investigator(s):
Principal Investigator, Eric Jenison, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0436. A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 136. Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU E1305. A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU E2805. A Randomized, Double-Blind, Phase III Trial of Adjuvant Sunitinib Vs. Sorafenib Vs. Placebo in Patients with Resected Renal Cell Carcinoma

Investigator(s):
Esther Rehmus, MD

Contact Information:

Go to top

Title(s):
CTSU E2902. A Phase III Randomized Study of Farnesyl Transferase Inhibitor R11577 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in a Remission after Primary Induction Failure or Patients over Age 60 in First Remission

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG E1905. A Randomized, Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplactic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia

Investigator(s):
Principal Investigator, Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG E5597. Phase III Randomized Chemoprevention Study of Selenium in Participants with Previously Resected Stage I Non-Small Cell Lung Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0517. Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breat and Prostate Cancer

Investigator(s):
Principal Investigator: Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0424. Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men

Investigator(s):
Principal Investigator: Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0617. A Randomized Phase III Comparison of Standard-Dose (60Gy) Versus Highdose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

Investigator(s):
Mitchell Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU E1505. A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>=4cm) - IIIA Non-Small Cell Lung Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU CALGB 30607. Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IB Non-Small Cell Lung Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0709. A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/Erlotinib or Erlotinib Alone in Advance Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS 2) Selected by Serum Proteomic

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU N0723. MARVEL Study: Marker Validation of Erlotinib in Lung Cancer a Phase III Biomarker Validation Study of Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Vs. Erlotinib

Investigator(s):
Principal Investigator, Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0802. A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU CALGB 30610. Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0819. A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0801. A Phase II Study of Iodine-131 Labeled Tositumomab in Combination with Cyclophosphamide Doxorubinin, Vincristin, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma

Investigator(s):
Principal Investigator: Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0438. A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R11577 (Tipifarnib; NSC-702818) in Metastatic Melanoma

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
CTSU CALBG 50303. Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated DeNovo Diffuse Large B-Cell Lymphomas

Investigator(s):
Principal Investigator: Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 212. Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients with Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673).

Go to top

Title(s):
GOG 0235. A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 0213. A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
GOG 0259. Nurse-Delivered Write Symptoms Versus Self-Directed Write Symptoms Care as Usual for Optimal Symptom Management for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator(s):
Eric Jenison, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0517. Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metatases from Lung, Breast and Prostate Cancer

Investigator(s):
Principal Investigator: Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0534. A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
SWOG 0421. Phase III Studyof Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0415. A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top

Title(s):
NSABP R-04. A Phase III Randomized Study of Preoperative Capecitabine and Radiotherapy Versus Fluorouracil and Radiotherapy in Patients with Resectable Rectal Cancer.

Investigator(s):
Principal Investigator: Andrew Fenton, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673).

Go to top

Title(s):
CTSU E2804. The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, mTOR Combination Targeted (CTT) with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal Cell Carcinoma.

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Center Research at 330-344-HOPE (4673)

Go to top

Title(s):
RTOG 0630. A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-HOPE (4673)

Go to top